Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MYL-1601D vs NovoLog in Type 1 Diabetes Mellitus
NCT03760068Phase 3Completed
- Sponsor
- Mylan
- Start
- Nov 2018
- Primary completion
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of myl-1601d in type 1 diabetes mellitus (T1D), sponsored by Mylan. Started Nov 2018; status: completed.
02
Drugs
myl-1601d
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03760068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03760068.